Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | GABRP | O00591 | 4/20 | 0.51 |
| ▸ | GABRD | O14764 | 4/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.51 |
| ▸ | GABRE | P78334 | 4/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13978661 | 0.83 | MAOA (0.47) | PAX8MAOAMAOBFTOACHE | |
| SCHEMBL428529 | 0.77 | CYP2A6 (0.47) | PTPN1PAX8MAOAMAOBALDH1A1 | |
| SCHEMBL29700330 | 0.77 | CYP2A6 (0.47) | PTPN1PAX8MAOAMAOBALDH1A1 | |
| SCHEMBL27612022 | 0.75 | MAOB (0.49) | MAOAMAOBALDH1A1CA12CA9 | |
| SCHEMBL9189119 | 0.73 | KDM1A (0.61) | PTPN1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3799970 | 0.73 | MAPT (0.46) | PAX8MAOAACHEALDH1A1HSD17B10 | |
| SCHEMBL9338329 | 0.73 | CA12 (0.51) | PTPN1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL25407064 | 0.72 | PTPN1 (0.43) | PTPN1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL29705824 | 0.72 | PARP1 (0.49) | PTPN1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4010048 | 0.72 | PTPN1 (0.57) | PTPN1GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023027630-A9 | A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-07-27 | — | — | WO | claimed |
| WO-2023027630-A2 | A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-03-02 | — | — | WO | claimed |
| US-7732534-B2 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION (JP) | 2010-06-08 | — | — | US | claimed |
| US-20080051519-A1 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION (JP) | 2008-02-28 | — | — | US | claimed |
| US-20080051552-A1 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION | 2008-02-28 | — | — | US | claimed |
| JP-1102530-A | — | — | None | — | — | JP | disclosed |
| US-20260128372-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEMICAL LTD (KR) | 2026-05-07 | — | — | US | disclosed |
| EP-4576305-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2025-06-25 | — | — | EP | disclosed |
| CN-120153509-A | Nonaqueous electrolyte for lithium secondary battery and lithium secondary battery comprising same | 株式会社LG化学 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024107030-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | 주식회사 엘지화학 | 2024-05-23 | — | — | WO | disclosed |
| CN-114560837-B | Chromone compound and preparation method and application thereof | 五邑大学 | 2023-11-24 | — | — | CN | disclosed |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-09-07 | — | — | US | disclosed |
| EP-1558582-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTIALS, INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2005012254-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-6756403-B2 | 6-AMINOCHROMAN-2-YL CARBOXYLIC ACIDS AND ESTERS AS PLATELET AGGREGATION INHIBITORS; FROM PHENOL AND KETOGLUTARIC ACID; OR FROM 2-HYDROXYACETOPHENONE AND DIETHYLOXALATE; OR FROM NITROPHENOL AND DIETHYL ESTER OF MALEIC ACID | ELI LILLY AND COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20040053992-A1 | Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor | ELI LILLY AND COMPANY | 2004-03-18 | — | — | US | disclosed |
| EP-1292589-A2 | METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | MILLENIUM PHARMACEUTICALS, INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094335-A2 | METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| JP-H01102530-A | ORGANIC NONLINEAR OPTICAL ELEMENT | HITACHI LTD | 1989-04-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | HTR2C, HTR2A, HTR5A | PTPN1 618/4885GABRP 414/4885GABRD 578/4885 |
| US-20260128372-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | CLCN2, CLIC1, RER1 | PTPN1 107/4885GABRP 4827/4885GABRD 4754/4885 |
| US-20040053992-A1 | Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor | NOTUM, FAR1, CYP51A1 | PTPN1 3946/4885GABRP 283/4885GABRD 300/4885 |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | PTPN1 629/4885GABRP 617/4885GABRD 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.